在与肥胖有关的心力衰竭中,塞马格卢提德和NYHA功能类与保存的喷射小部分:STEP-HFpEF程序
Morten Schou1, Mark C Petrie2, Barry A Borlaug3
1Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev, Denmark.
Journal of the American College of Cardiology
|June 24, 2024
概括
塞马格卢提德显著改善了纽约心脏协会 (NYHA) 在患有与肥胖有关的心力衰竭患者的功能类,并保留了喷射分数 (HFpEF). 该药物减少了症状负担,并在所有NYHA课程中改善了身体功能.
科学领域:
- 心脏病学 心脏病学
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 在症状管理和功能能力方面,与肥胖相关的心力衰竭与保存的喷射分数 (HFpEF) 存在重大挑战.
- 在肥胖患者和HFpEF (STEP-HFpEF) 计划中,塞马格卢提德治疗效果证明了塞马格卢提德对HF症状,身体限制,运动功能和体重的好处.
- 塞马格卢提德对功能状态的影响,特别是NYHA功能类,仍有待阐明.
研究的目的:
- 在52周内,在患有与肥胖相关的HFpEF的患者中,评估塞马格卢提德对NYHA功能类变化的影响.
- 通过基线NYHA功能类别分层对HF症状,身体限制,体重和其他试验终点进行调查.
主要方法:
- 一个预先规定的分析两个国际,双盲,随机化试验 (STEP-HFpEF和STEP-HFpEF DM) 的汇总数据,涉及1,145名参与者.
- 与肥胖相关的HFpEF的参与者每周接受一次2.4毫克或安慰剂的52周.
- 主要结局是从基线到52周的NYHA功能类的变化,在基线NYHA功能类类别中分析了二级和探索性终点.
主要成果:
- 更多接受塞马格卢提德治疗的患者在NYHA功能类中表现出改善 (32.6%与安慰剂21.5%相比) 和较少的经历恶化 (2.09%与安慰剂5.24%).
- 在所有NYHA类中,塞马格卢提德改善了堪萨斯城心肌病问卷-临床总结得分 (KCCQ-CCS),在NYHA类III/IV中更有好处.
- 在6分钟步行距离 (6MWD),层次复合终点和生物标志物 (C-反应蛋白,NT-proBNP) 的减少方面,无论基线NYHA类,都观察到与semaglutide一致的改善.
结论:
- 在52周的时间内,塞马格卢提德治疗导致肥胖相关HFpEF患者的NYHA功能类显著改善和减少恶化.
- 该药物在所有NYHA功能类别中对高压症状,身体限制,运动功能,体重和生物标志物表现出一致的好处.
- 塞马格卢提德介导的健康状况改善在具有更严重功能限制 (NYHA III/IV类) 的患者中尤为明显.
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
420
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:23Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:26Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564